A Pilot Study Investigating the Effect of Omalizumab (Xolair) in Work-Related Animal Induced Asthma

• Status: Withdrawn
• Trial end date: 2009-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Management of animal induced occupational asthma is mainly avoidance, but this is not feasible for many occupations. Treatment with avoidance and conventional treatment is also not always successful. Omalizumab is FDA approved for the treatment of allergic asthma and may be effective at reducing symptoms and disease progression in the animal handlers population.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bernstein Clinical Research Center
• Treatments: Omalizumab

Criteria

Inclusion Criteria:

1. ages 18-65

2. occupation that involves close contact with animals

3. stable dose of ICS for 30 days

4. Skin test positive to one or more animals

5. evidence of asthma on spirometry

6. demonstrate PEFR variability-

Exclusion Criteria:

1. on allergen immunotherapy

2. on prohibited medications

3. unstable asthma

4. recent URI

5. known hypersensitivity to omalizumab-